Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
Inhibition of platelet function by means of dual antiplatelet therapy (DAPT) is the cornerstone of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences, inhibition of platelet function is clearly associated with an increased bleeding risk, a feared complication that may...
Main Authors: | Gregorio Tersalvi, Luigi Biasco, Giacomo Maria Cioffi, Giovanni Pedrazzini |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/7/2064 |
Similar Items
-
Early discontinuation of dual antiplatelet therapy via acetylsalicylic acid cessation in patients with acute coronary syndrome undergoing percutaneous coronary interventions to reduce the bleeding risk
by: O. V. Averkov
Published: (2021-02-01) -
No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
by: Viviana Laredo, et al.
Published: (2020-05-01) -
Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01) -
Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease
by: Chor-Cheung Tam, et al.
Published: (2022-12-01) -
The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention
by: A. S. Tereshchenko, et al.
Published: (2019-05-01)